A literature covering 150 years of research indicates that macrophages are a diverse family of professional phagocytes that continuously explore their environment, recognize and scavenge pathogens, unfit cells, cell debris as well as metabolites, and produce a large range of bioactive molecules and growth factors. A new paradigm suggests that most tissue-resident macrophages originate from fetal precursors that colonize developing organs and self-maintain independently of bone marrow-derived cells throughout life. The differentiation of these precursors is driven by a core macrophage transcriptional program and immediately followed by their specification through expression of tissue-specific transcriptional regulators early during embryogenesis. Despite our increasing understanding of ontogeny and genetic programs that shape differentiation processes and functions of macrophages, the precise developmental trajectories of tissue-resident macrophages remain undefined. Here, I review current models of fetal hematopoietic waves, possible routes of macrophage development and their roles during homeostasis. Further, transgenic mouse models are discussed providing a toolset to study the developmentally and functionally distinct arms of the phagocyte system in vivo.
Introduction
In 1882, Elie Metchnikoff performed experiments in star-fish larvae that became the foundation of the phagocytosis theory, which accounts for the diverse functions of phagocytes in development and in adult physiology. Being an embryologist, he initially traced mesoderm-derived 'wandering amoeboid' cells throughout phylogeny. He recognized that these cells ingested to feed themselves but also that they 'accumulate and unite into masses', thereby playing a causal role in tissue resorption during development (1) . Metchnikoff further suggested cell accumulation to be an active 'amoeboid cell function' during inflammation and postulated that inflammation is beneficial for the host-a hypothesis that was largely rejected by professional pathologists at the time. Nevertheless, Metchnikoff managed to successfully defend his phagocytosis theory and is nowadays unanimously considered the founding father of the innate immunity research.
In the early decades of the 20th century, phagocytes-originally named by Metchnikoff from the Greek from phagein: 'eat' and kutos: 'vessel'-have been variously termed reflecting their diverse functionalities and locations: pyrrhol cells, adventitia cell, rhagiocrine cells, resting wandering cells, endothelial leukocytes, clasmatocytes, histiocytes and macrophages-just to name a few (2) . Although Ludwig Aschoff unified this group of cells by a systematic analysis of histological stains, tissues, anatomy and morphology into the reticuloendothelial system in 1924 (3), the origin of macrophages remained a source of confusion and debate.
During the second part of the 20th century, van Furth and colleagues proposed the mononuclear phagocyte system as a developmental pathway for macrophage ontogeny and differentiation (4), supported by observations from bone marrow transplantation in irradiated hosts, peritonitis models and extensive in vitro studies (5) (6) (7) (8) . This classical textbook model holds that macrophages originate and renew from circulating bone marrow-derived monocytes, which extravasate into tissues where they mature into tissue macrophages. In this model, the recruitment of macrophages from their circulating precursors is regulated by inflammation, and increased numbers of macrophages are present in infected and inflamed tissues. Inflammation also controls their functions by external cues-most prominently through the cytokines interferongamma and interleukin-4-thereby polarizing macrophages towards distinct effectors functions (9) .
This model was not always consistent with analyses of parabiosis (10), thymidine incorporation (11), as well as bone marrow chimera experiments (7) from the 1980s and 1990s, which suggested that around half of myeloid cells found in the brain, lung, liver, peritoneum and spleen were dependent on local proliferation rather than monocyte recruitment. Moreover, numerous developmental studies in rodents implied that resident macrophage populations are set up very early in fetal tissues, well before white cells colonize the spleen, bone marrow and other future blood-forming regions (12) (13) (14) (15) (16) . Following up on the initial characterization by del Rio-Hortega (15) , it was actually shown in 1999 that microglia, the tissue-resident macrophage of the brain, are derived from cells originating from the yolk sac (YS), whose progeny actively proliferates in situ during development (17) . Using genetic fate-mapping strategies, the fetal origin of not only postnatal microglia (18) , but also the majority of other resident macrophages was proven (19) (20) (21) (22) . The fact that resident macrophages are long-lived, self-maintain and do not renew from bone marrow hematopoietic stem cells (HSCs) in most adult murine tissues led to a paradigm shift in our understanding of macrophage development and function.
Fetal hematopoietic waves-the origin(s) of tissue-resident macrophages
In the mouse embryo, hematopoietic cell development occurs asynchronously in several waves and at multiple anatomic locations (Fig. 1) . The first wave-or primitive hematopoiesis-starts extra-embryonically at embryonic day (E) 7.5 when primitive erythroid progenitors are first detected in the YS and give rise to primitive erythroblasts (23) (24) (25) . In vitro studies in mouse and in vivo work in zebrafish suggests that the first wave of hematopoiesis can also give rise to macrophages (25, 26, 27) . Further, the very first parenchyma microglia can be detected already at E8 and thus before the onset of the second wave (17) , suggesting a direct primitive macrophage progenitor for at least the initial wave of microglia. Therefore, the development of microglia may not require any progenitors that arise during the subsequent hematopoietic waves (see below). Yet, murine in vivo data supporting this hypothesis could not be unequivocally provided due to the lack of markers or tools that could reliably distinguish macrophages based on the hematopoietic origin.
In the second wave-or transient hematopoiesis-erythromyeloid progenitors (EMPs) emerge in the YS, colonize the fetal liver and contain monocyte, granulocyte, megakaryocyte, mast cell, erythroid and macrophage potential (25) (26) (27) (28) (29) . EMPs develop from YS hemogenic endothelia between E8.5 and E10.5 (19, 30) . Differentiation from EMPs to macrophages goes through an intermediate pre-macrophage (pMac) stage, a Cx3cr1-expressing precursor distinct from monocytes (31) . EMPs and pMac expand in the YS and enter the blood stream to migrate towards the embryo, with a trafficking peak at E10.5 (32) . The chemokine receptor Cx3cr1 is crucial for the colonization of peripheral tissues by pMac. Cx3cr1-deficient embryos show decreased pMac and macrophage numbers in the head and limbs of E9.5 and E10.5 Model of mouse macrophage development and heterogeneity. Mesoderm-derived hematopoiesis starts from embryonic day (E) 7.5 and can give rise to macrophages at least in vitro (first hematopoietic wave). EMPs emerge in the YS around E8.5 and differentiate into pMac, which give rise to fetal macrophages that self-maintain and mature into postnatal resident macrophages in vivo (second wave of hematopoiesis). Both, EMPs and pMac can migrate to the fetal liver (FL). EMP-derived monocytes may also give rise to long-lived macrophages. Within the embryo proper, HSCs develop in the aorta-gonad-mesonephros (AGM) at E10.5 as the third hematopoietic wave. HSCs migrate first to the fetal liver, and at E17.5, to the bone marrow (BM), where they persist and self-renew. HSCs continuously give rise to monocytes that are constantly recruited to tissues. A fetal HSC-derived macrophage origin is debated. embryos in comparison with Cx3cr1 +/− littermates, while they accumulate in the YS and fetal liver (31, 32) . EMPs are rarely found in the circulation of peripheral tissues (E. Mass, unpublished data). Instead, a large proportion of EMPs remain in the fetal liver-at least until E14.5 (19, 30 )-where they may serve as a reservoir of macrophages for developing tissues throughout embryogenesis.
The third wave-or definitive hematopoiesis-comprises HSCs. They can be distinguished from other hematopoietic progenitors by their self-renewal capacity, their presence in adults and their repopulation potential after transplantation (33) . HSCs emerge intra-embryonically from the hemogenic endothelium in the aorta-gonad-mesonephros region and in the umbilical and vitelline arteries at E10.5 (26, 34, 35) . They migrate to the fetal liver, where they expand and differentiate. Definitive hematopoiesis begins to shift to the bone marrow around E17.5, when the bone marrow cavity is formed. While most cells of the first two hematopoietic waves will ultimately be replaced by definitive hematopoiesis, an HSC origin for tissue-resident macrophages remains controversial (36-41).
Do we need monocytes to make macrophages?
Intriguingly, fetal EMP-derived monocytes have been proposed as the main source of postnatal macrophages-with the exception of the brain-replacing the early EMP-derived macrophages during organogenesis. This has been mainly based on fate-mapping experiments utilizing the monocytespecific S100a4 promoter that labels the majority of macrophages by E16.5 (39) . Yet, pMac also express S100a4 (31) and therefore cannot be unambiguously excluded as the main progenitor of macrophages.
Another possibility could be that pMac and monocytes are two interdependent entities along the developmental trajectory from EMP to macrophage. However, the emergence of EMP-derived pMac precedes the first onset of EMP-derived monocytes by approximately 2 developmental days, which suggests that pMac and monocytes are distinct progenitors. Nevertheless, alongside with pMac, EMP-derived monocytes may also serve as a source for tissue-resident macrophages ( Fig. 1 ). Yet, the exact developmental time windows and tissues in which these distinct precursors differentiate into macrophages remain to be investigated. An alternative model proposes that HSC-derived monocytes give rise to most macrophages using Kit MeriCreMer as a fate-mapping model (38) . However, Kit is expressed by progenitors of all three hematopoietic waves and could thus never delineate EMP-from HSC-derived cells.
Taken together, the current models of macrophage ontogeny rely mainly on genetic fate-mapping techniques, which so far all have intrinsic limitations such as efficiency, haploinsufficiency and the intercalating developmental time windows of the three hematopoietic waves, thus not allowing us to definitively conclude on only one progenitor. A possible solution to corroborate or dismiss a fetal EMP-or HSC-derived monocytic intermediate for postnatal macrophages could be a combination of fate-mapping both lineages and genetic knockout models of (transcription) factors indispensable for monocyte development.
Specification of tissue-resident macrophages
Tissue-resident macrophages are a diverse family of cells that are found in most organs. They possess general abilities of a phagocyte, independent of their location; however, they are also equipped with very specific functions that depend on the tissue they reside in. Sophisticated fate-mapping, parabiosis and adoptive transfer experiments indicate that the majority of these heterogeneous tissue macrophages are fetus-derived and show none or only a minor contribution from HSCs upon aging. This resident macrophage diversity is established early during organogenesis and is expanded by a small population of bone marrow-derived phagocytes under steady state that are short-lived and constantly recruited to tissues (Fig. 1) .
Tissue-resident macrophage identity as well as their heterogeneity is established by transcriptional networks very early during embryogenesis. A core macrophage transcriptional program drives differentiation of EMP into pMac (Table 1) . Subsequently, early F4/80 + macrophages undergo characteristic differentiation trajectories in their tissue of residence, which are determined by the preferential and progressively enriched expression of tissue-specific transcriptional regulators (31) . Many of these factors that drive the certain functions of a tissue-specific macrophage have been functionally validated by knockout mice and are summarized in Table 2 . Yet, our knowledge is still limited, particularly due to the presence of several resident macrophage subpopulations per tissue that have not always been taken into account in transcriptional studies. One such example is the brain, where besides the predominant macrophage population of microglia, fetus-derived meningeal and perivascular macrophages occupy their distinct niches. Unbiased single cell analyses should address additional transcriptional networks and factors essential for macrophage development and specificity in the future.
In contrast, recruited macrophages from the bone marrow usually do not show a tissue-specific function but rather act generally as immune sentinels under steady state conditions. Studies now progressively pinpoint distinct responses and functions of these two ontogenetically diverse macrophages subtypes, usually under inflammatory conditions. But how are we supposed to understand the full picture of diversity after injury, if we are still lacking information during homeostasis? It is likely that further functional and ontogenetic heterogeneity exists within tissues, as seen in the brain, where 'macrophages' is just an umbrella term encompassing at least four different phagocyte types, depending on the area of the brain they reside in. Whether the diversity among resident macrophages that populate distinct anatomical microenvironments within an organ is relevant to development and postnatal homeostatic functions of a tissue remains to be investigated. Only then will we be able to fully appreciate the role of macrophages in disease onset and progression.
Genetic instruction versus tissue education
Although mouse models emphasize that many tissue-resident macrophages are fetus-derived, their exact cell of origin is still intensely debated (36) (37) (38) (39) (40) (41) . But why should we care at all where these cells come from, if we want to study their functions in homeostasis and diseases in adults? The origin of a cell may dictate cell survival, colonization of certain tissue niches and thereby also distinct functions under steady state and during inflammation and repair. These events and functions could be guided by early epigenetic processes that would subsequently prohibit full reprogramming of macrophages. New technologies such as RNA-sequencing (RNA-seq), DNA methylation and ChIP-seq on a single cell level will assess if fetal macrophage progenitors follow tissue-specific differentiation trajectories that are endogenously driven, which in turn could result in drug therapies successfully targeting macrophages.
Indeed, a recent study comparing YS progenitors and fetal microglia by single cell RNA-seq suggests on the one hand the presence of a heterogenous progenitor population in the YS, and on the other hand a microglia-specific transcriptional signature in some of these YS subpopulations (76) . This observation strongly supports the hypothesis of an early commitment to the microglia fate. Nevertheless, the question whether macrophage progenitors are genetically hard-wired or instructed by the environment remains a matter of debate.
This nature versus nurture argument may be a deceptive dichotomy because control by ontogeny versus control by tissue environment are probably not mutually exclusive. If environmental cues play a major role in macrophage differentiation and educate a rather homogenous population of circulating and extravasating progenitors, they have to be initiated in the developing organs. We know that the transcriptome of postnatal tissue-resident macrophages can be influenced by a new environment when transferred from one organ to another. However, only few cells recover and the survivors are not able to acquire new functions required in the new niche (77, 78) . Less mature, but already differentiated macrophages from the YS show a better potential to stably occupy an empty niche, and fetal monocytes even outcompete these macrophages (77) . Thus, a certain plasticity of a cell must be given to (re)differentiate it into a functional cell.
Yet, this competition is rather artificial and lacking in physiological competitiveness, since in the in vivo situation undifferentiated pMac would co-exist with fetal monocytes, both of which could colonize developing tissues during development. However, it remains challenging to study these differentiation events in vivo, as tools are missing to discriminate and follow all three hematopoietic waves in the same animal. For future studies, we should keep in mind that the potential of a cell that is exposed to an empty niche, thereby enforcing an artificial plasticity, neither shows its actual fate nor represents differentiation events happening under steady state conditions. Therefore, understanding the heterogeneity of progenitors and the underlying mechanisms that drive macrophage specification during development is crucial to understand the functionality of macrophages later in life.
Models to study macrophage function in health and disease
Various mouse models have been established to study the function of tissue-resident and bone marrow macrophages. A broadly used approach is the general depletion of macrophages by clodronate. Although this method is fast and feasible to combine with disease models, e.g. liver fibrosis (79) or cancer (80, 81) , it is very unspecific as it does not target specific organs or delineate fetus versus bone marrow-derived myeloid lineages. In addition, it depletes dendritic cells and therefore by no means represents a macrophage-specific depletion strategy (82, 83) . Another inducible approach is the diphtheria toxin receptor (DTR)-mediated conditional system. Driving DTR expression with a general or tissue-specific macrophage Cre recombinase line or under the control of a promoter with subsequent administration of DT allows a relatively specific depletion [e.g. LysM-Cre/DTR (84), CD11b-DTR (85), CD169-DTR (86), Langerin-DTR (87, 88), Clec4f-DTR (89)]. The downside of DTR models is that this chemical-induced ablation does not represent homeostatic conditions as it induces uncontrolled, systemic inflammation (90) . Thus, the DT dose has to be carefully titrated and wild-type littermates have to be DT-treated as well to control for unspecific effects, especially in combination with disease models (91, 92) .
In contrast, genetic models that target distinct myeloid lineages may rather represent steady state conditions and allow us to study macrophage development and functions not only by conditional knockouts, but also by genetic fatemapping. The Cre/loxP site-specific recombination system has emerged as an important tool to control gene activity in a spatiotemporal manner in almost any tissue of the mouse. This technique opened new avenues for studying not only the gene function but also the cell ontogeny, thereby leading to the experimental discovery of fetus-derived postnatal macrophages (18, 22) . However, Cre mouse lines-constitutive or inducible-also have their pitfalls and have led to many studies where results have been misinterpreted because the authors assume that (i) the Cre is tissue-or cell-specific and not expressed anywhere else, (ii) inducible Cre is 100% efficient or (iii) Cre transgene (when replacing the endogenous gene locus) would not affect developmental processes. Haploinsufficiency of transcription factors is frequently observed and should be avoided in the experimental setup. One such example is the Runx1
MerCreMer line that was initially used to fate-map microglia (18) . Yet, in this transgenic model, one Runx1 allele is inactivated, which impacts hematopoietic cell development and lineage decisions (93) (94) (95) .
To discriminate between fetus-and adult HSC-derived macrophages, many tools have been established such as HSC-specific Cre mice, parabiosis and adoptive transfers after irradiation or genetically mediated bone marrow depletion. However, these approaches enabled us to study mainly functions of HSC-derived cells. To target resident macrophages, the Cx3cr1
CreER line can be used (Table 3 ) (20) . Although tamoxifen injection in the adult mouse will also label monocytes, they are short-lived and will not contribute to the resident macrophage pool. Short-comings of this inducible Cre model is that in adult mice, only Cx3cr1-expressing macrophages such as microglia and kidney macrophages will be targeted. If the injection is performed during embryogenesis, it will target resident macrophages in most tissues, but the labeling efficiency remains usually under 10% outside the brain. As all pMac and fetal macrophages express Cx3cr1, several consecutive tamoxifen pulses could lead to a higher labeling efficiency, but this is a method that is usually not well tolerated by pregnant females. Thus, until recently an efficient Cre mouse line specific for tissue-resident macrophages that would not affect HSC-derived cells was lacking.
Analysis of the fetal core macrophage program in pMac revealed many candidate genes that would be important for macrophage differentiation (31) . We could show that the Tnfrsf11a
Cre line, which has been used before to target osteoclasts (101), targets only ~10% of HSCs but very efficiently (80-90%) targets all tissue-resident macrophages, although they lose expression of Tnfrsf11a (31) . Thus, the Tnfrsf11a
Cre line provides a novel tool to target tissue macrophages.
To raise the awareness for advantages and disadvantages of inducible models to fate-map and study myeloid cells, commonly available Cre models, and which cells they target depending on the injection time point, are summarized in Table 3 .
Practical considerations for tissue-specific macrophage knockouts
To study the function of tissue-specific macrophages during embryogenesis, and in adult mice under homeostatic conditions, one could combine Tnfrsf11a
Cre and conditional alleles of genes that would be essential for the development of the population of interest: e.g. the number of Kupffer cells can be reduced by knocking out Id3 (31), while microglia could be targeted by knocking out Sall1. To study the functions of genes that are broadly expressed, one could use or generate a Cre line, that would be expressed specifically only in one macrophage population (e.g. Clec4f
Cre for Kupffer cells, Sall1
Cre for microglia, Langerin Cre for Langerhans cells) to delete conditional alleles.
Good practice rules for genetic targeting
When using conventional Cre systems, the experimenter has to be aware that expression of a certain gene and thus also of the Cre, which is under the control of that gene, can always be acquired by a cell population-either by environmental influence such as ageing or by inflammation. Inducible Cre lines have the benefit of specifically labeling the progeny of Cre-expressing cells over months, which allows us to conclude on the origin of a cell even under inflammatory conditions. However, one tamoxifen pulse rarely labels 100% of cells. This becomes critical during genetic fate-mapping in development where the transition from one to the next hematopoietic wave is fast and fluent, thus not allowing multiple tamoxifen pulses. Consequently, incomplete targeting efficiency of the population of interest should not be interpreted as an indicator for another origin but could simply represent developmental windows that one hits with the pulse.
Of note, both tamoxifen and 4-hydroxytamoxifen (4-OHT) are used for genetic fate-mapping. 4-OHT is the main metabolite of tamoxifen whose conversion takes place in the liver. Despite tamoxifen being cheaper, 4-OHT should be used for fate-mapping of hematopoietic progenitors as it confines the time window of Cre recombinase activity. When recombination is required over a longer time period during embryogenesis (e.g. using Cx3cr1
CreER to target the majority of fetal macrophages independently of the progenitor) or performed postnatally, tamoxifen can be used.
Recombination efficiencies of conditional alleles after tamoxifen administration should be confirmed by PCR and can be monitored by a reporter (e.g. Rosa26 LSL-YFP ) in experimental animals. Finally, an important control are animals that have not been injected with tamoxifen, especially when pulse labeling during postnatal stages, as the inducible Cre may become active with time despite the lack of tamoxifen (105) .
Conclusion
In a simplistic model, resident macrophages are responsible for the basic developmental and homeostatic functions of phagocytes, while recruited macrophages would mediate inflammatory responses. An additional level of heterogeneity is established by resident macrophages themselves within a given tissue, which is relevant for diverse tissue functions during steady state. This heterogeneity may be established through cell-intrinsic mechanisms on transcriptional and epigenetic levels in macrophage progenitors such as EMPs, pMac or fetal monocytes, or by cell-extrinsic cues of the distinct developing anatomical niches that would promote sequential colonization of progenitors, or by the co-existence of distinct macrophage precursors and their progeny within the same organ. The latter would support a model where 'replacement' of EMP-derived fetal macrophages does not take place by fetal monocytes-as previously proposed (37, 106)-but where pMac, EMP-derived monocytes and possibly HSC-derived monocytes give rise to distinct macrophage populations. Especially in dynamic processes such as the developing hematopoietic system, the concept of a continuum of cellular states may be more appropriate than rigid cell-type categorizations. Therefore, single cell analyses of the fetal hematopoietic system combined with genetic fate-mapping and in situ analyses should reveal differentiation and maturation trajectories that would allow us to identify spatio-temporally restricted patterns that drive macrophage development during organogenesis and the establishment of inter-and intraorgan heterogeneity. Conflicts of interest statement: the author declared no conflicts of interest.
